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A bs tr ac t
Background
Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is 
ideal for control of this condition. Experimental studies suggest that angiotensin II–
receptor blockers (ARBs) can influence atrial remodeling, and some clinical studies 
suggest that they may prevent atrial fibrillation.
Methods
We conducted a large, randomized, prospective, placebo-controlled, multicenter trial 
to test whether the ARB valsartan could reduce the recurrence of atrial fibrillation. 
We enrolled patients who were in sinus rhythm but had had either two or more 
documented episodes of atrial fibrillation in the previous 6 months or successful 
cardioversion for atrial fibrillation in the previous 2 weeks. To be eligible, patients 
also had to have underlying cardiovascular disease, diabetes, or left atrial enlarge-
ment. Patients were randomly assigned to receive valsartan or placebo. The two pri-
mary end points were the time to a first recurrence of atrial fibrillation and the pro-
portion of patients who had more than one recurrence of atrial fibrillation over the 
course of 1 year.
Results
A total of 1442 patients were enrolled in the study. Atrial fibrillation recurred in 371 
of the 722 patients (51.4%) in the valsartan group, as compared with 375 of 720 
(52.1%) in the placebo group (adjusted hazard ratio, 0.97; 96% confidence interval 
[CI], 0.83 to 1.14; P = 0.73). More than one episode of atrial fibrillation occurred in 
194 of 722 patients (26.9%) in the valsartan group and in 201 of 720 (27.9%) in the 
placebo group (adjusted odds ratio, 0.89; 99% CI, 0.64 to 1.23; P = 0.34). The results 
were similar in all predefined subgroups of patients, including those who were not 
receiving angiotensin-converting–enzyme inhibitors.
Conclusions
Treatment with valsartan was not associated with a reduction in the incidence of 
recurrent atrial fibrillation. (ClinicalTrials.gov number, NCT00376272.)
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A trial fibrillation is the most com-mon cardiac arrhythmia.1-5 Antiarrhythmic drugs have only moderate efficacy in pre-
venting recurrences of atrial fibrillation and some-
times cause serious adverse reactions.6-8 Ablation 
is a costly procedure, and accepted indications are 
limited.9,10 Thus, new approaches to the manage-
ment of atrial fibrillation continue to be the sub-
ject of interest and investigation.
Some studies have shown that the recurrence 
of atrial fibrillation after cardioversion may be 
partially related to a biologic phenomenon known 
as remodeling, in which the electrical, mechani-
cal, and structural properties of atrial tissue and 
cardiac cells are progressively and irreversibly al-
tered, creating a more favorable substrate for atrial 
fibrillation.11-13 The renin–angiotensin–aldoste-
rone system plays a role in atrial remodeling. In 
animal models of atrial fibrillation, blockade of 
the renin–angiotensin–aldosterone system with 
the use of an angiotensin-converting–enzyme 
(ACE) inhibitor or an angiotensin II–receptor 
blocker (ARB) has been shown to favorably af-
fect electrical and structural remodeling of the 
atrium.14-17
Several clinical studies have suggested that ACE 
inhibitors or ARBs may have a beneficial effect 
on either new-onset atrial fibrillation (i.e., primary 
prevention) or recurrent atrial fibrillation (i.e., 
secondary prevention). However, in those stud-
ies, either atrial fibrillation was assessed as an 
ancillary variable18-24 or it was the main end point 
but the study was too small to definitively estab-
lish an effect on the incidence or recurrence of 
atrial fibrillation.25-28 Published meta-analyses have 
reached contrasting conclusions on the effects 
of inhibitors of the renin–angiotensin–aldo ste rone 
system.29,30 We conducted the Gruppo Italiano 
per lo Studio della Sopravvivenza nell’Infarto 
Miocardico–Atrial Fibrillation (GISSI-AF) trial 
to assess whether the addition of the ARB valsar-
tan to established therapies could reduce the rate 
of recurrence of atrial fibrillation in patients with 
a history of that arrhythmia.
ME THODS
Study Design
The rationale and the design of this study have 
been described previously.31 The GISSI-AF study 
was a prospective, multicenter, randomized, dou-
ble-blind, placebo-controlled trial. It was designed 
and supervised by the steering committee (see the 
Appendix) and approved by the ethics committee 
at each participating center. Funding was provided 
by Novartis, which had no role in the design or 
conduct of the trial; the collection, analysis, or in-
terpretation of the data; or the writing of the re-
port. The authors vouch for the accuracy and com-
pleteness of the data and the analysis.
Patients
Patients of either sex were eligible for inclusion in 
the study if they were at least 40 years of age and 
had had either two or more episodes of symptom-
atic atrial fibrillation (as documented on an elec-
trocardiogram) in the previous 6 months or suc-
cessful cardioversion (electrical or pharmacologic) 
for atrial fibrillation between 14 days and 48 hours 
before randomization. All patients had to have 
been in sinus rhythm for at least 2 days before 
randomization. In addition, patients had to have 
at least one of the following conditions: heart fail-
ure or a documented history of left ventricular 
dysfunction (defined as an ejection fraction of less 
than 40%); a history of hypertension for 6 months 
or more, with or without left ventricular hypertro-
phy; type 2 diabetes; a history of stroke or periph-
eral artery disease; a history of coronary artery 
disease; or atrial fibrillation without coexisting 
cardiovascular conditions but with left atrial dil-
atation (defined as a left atrial diameter of 45 mm 
or greater in men or 40 mm or greater in women).
Patients were excluded if they required treat-
ment with ARBs for another indication; had con-
traindications to ARBs; had recently (within the 
previous 6 weeks) had an acute myocardial infarc-
tion, coronary bypass operation, or percutaneous 
coronary intervention; had clinically significant 
valvular disease; had thyroid dysfunction; or were 
scheduled to undergo catheter ablation or implan-
tation of a pacemaker or defibrillator.
All participants had to have been on a stable 
regimen of treatment for atrial fibrillation and 
for any underlying cardiovascular disorders for at 
least 1 month before enrollment. Patients were al-
lowed to continue all previously prescribed treat-
ments for these conditions (including ACE inhibi-
tors, amiodarone, and beta-blockers). All eligible 
patients provided written informed consent be-
fore enrollment.
Randomization and Study Treatment
Eligible patients were randomly assigned to either 
valsartan or matching placebo by means of a com-
puterized, telephone randomization system, with 
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the group assignments concealed. Randomization 
was based on stratification according to site, with 
blocks of four patients per site. The study drug 
was initiated at a dose of 80 mg daily for 2 weeks 
and was then increased to 160 mg daily for an-
other 2 weeks. At the 4-week visit, the dose was 
increased to 320 mg daily, and this regimen was 
continued until the end of the follow-up period at 
week 52.
Upward adjustment of the dose of the study 
medication was required for all patients unless 
they presented with a blood pressure below 
110/65 mm Hg or symptomatic hypotension. If 
a patient could not tolerate a daily dose of 160 mg, 
the dose was reduced to 80 mg, and attempts were 
subsequently made to increase the dose again. If 
the patient could not tolerate a dose of at least 
160 mg of the study drug within 2 months after 
enrollment, the study drug was withdrawn.
Follow-up
Study visits were scheduled at weeks 2, 4, 8, 24, 
and 52, with the follow-up period concluding at 
1 year. A routine clinical examination, including 
Table 1. Baseline Characteristics of the Patients According to Study Group.*
Characteristic
Valsartan 
(N = 722)
Placebo 
(N = 720) P Value
Age — yr 67.5±9.5 68.2±8.9 0.14
Female sex — no. (%) 267 (37.0) 277 (38.5) 0.56 
Body-mass index† 28.0±4.5 27.7±4.2 0.19
≤5 yr of education — no. (%) 334 (46.3) 353 (49.0) 0.26
Blood pressure — mm Hg
Systolic 138.2±16.7 139.0±16.9 0.40
Diastolic 81.5±8.5 81.6±9.0 0.92
Inclusion criteria — no. (%)
≥2 episodes of atrial fibrillation in previous 6 mo 299 (41.4) 282 (39.2) 0.45
Cardioversion in previous 2 wk 646 (89.5) 630 (87.5) 0.24
Duration of last qualifying episode of atrial fibrillation >7 days 238 (33.0) 225 (31.2) 0.49
Heart failure, LVEF <40%, or both 56 (7.8) 58 (8.1) 0.83
History of hypertension for 6 mo or more 619 (85.7) 612 (85.0) 0.69
Diabetes mellitus 95 (13.2) 116 (16.1) 0.11
History of stroke 32 (4.4) 27 (3.8) 0.51
Peripheral artery disease 37 (5.1) 22 (3.1) 0.047
Documented coronary artery disease 111 (15.4) 68 (9.4) ≤0.001
Atrial fibrillation alone‡ 78 (10.8) 94 (13.1) 0.19
Coexisting conditions — no. (%)
Peripheral embolism 3 (0.4) 7 (1.0) 0.20 
Previous transient ischemic attack 28 (3.9) 26 (3.6) 0.79 
Renal dysfunction 24 (3.3) 16 (2.2) 0.20 
Chronic obstructive pulmonary disease 50 (6.9) 56 (7.8) 0.54 
Neoplasia 22 (3.0) 23 (3.2) 0.87 
Current smoker 57 (7.9) 64 (8.9) 0.50 
Alcohol abuse 6 (0.8) 11 (1.5) 0.22 
Electrocardiographic findings at randomization
Heart rate — bpm 63.5±10.5 63.7±10.5 0.68 
QRS interval >120 msec — no. (%) 57 (7.9) 70 (9.7) 0.22 
Left ventricular hypertrophy — no. (%) 71 (9.8) 60 (8.3) 0.32 
Pathologic Q waves — no. (%) 41 (5.7) 22 (3.1) 0.02 
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electrocardiography and laboratory testing, was 
performed at each study visit. To increase the like-
lihood that atrial fibrillation could be detected, 
all patients were provided with a transtelephonic 
monitoring device (Cardiobios 1, Telbios). The pa-
tients were asked to activate this device, which 
would transmit a 30-second electrocardiogram to 
both the coordinating center and the responsible 
physician, if symptoms occurred and at least once 
a week whether or not symptoms occurred. If a 
recurrence of atrial fibrillation was detected, the 
patient was asked to come in for an office visit to 
confirm the findings.
Study End Points
The study was designed with two primary end 
points: the time to the first recurrence of atrial 
fibrillation and the proportion of patients who 
had more than one episode of atrial fibrillation 
over the 1-year follow-up period. Secondary end 
points included the total number of episodes of 
atrial fibrillation per patient, hospitalization for 
any reason and hospitalization for a cardiovascu-
lar event, the composite of death and thrombo-
embolic events, the number of patients in sinus 
rhythm at the time of each study visit, the dura-
tion of and ventricular rate at the first recurrence 
of atrial fibrillation, and a safety profile. A pre-
defined analysis of the effects of valsartan as com-
pared with placebo on the recurrence of atrial fi-
brillation was also performed for patients who 
were in sinus rhythm 15 days after study entry, 
with the aim of assessing the effect of valsartan 
after the exclusion of early recurrences of atrial 
fibrillation. A similar post hoc analysis included 
patients who were in sinus rhythm at week 8, by 
which time it was expected that patients would 
be receiving the target dose of valsartan. An in-
dependent end-point committee adjudicated all 
reports of primary end points, deaths, and hospi-
talizations.
Statistical Analysis 
The estimated sample size was based on the time 
to the first recurrence of atrial fibrillation. We cal-
culated that for the study to have 88% power to 
detect a 17.6% relative difference between the val-
sartan and placebo groups, there would have to 
be 599 events, assuming an event rate in the pla-
cebo group of 50% at 1 year (which corresponds 
Table 1. (Continued.)
Characteristic
Valsartan 
(N=722)
Placebo 
(N=720) P Value
Concomitant cardiovascular therapies — no. (%)
Amiodarone 253 (35.0) 248 (34.4) 0.81
Sotalol 53 (7.3) 47 (6.5) 0.54
Class I antiarrhythmic agents 235 (32.5) 232 (32.2) 0.89
ACE inhibitors 420 (58.2) 402 (55.8) 0.37
Calcium-channel blockers 207 (28.7) 221 (30.7) 0.40
Beta-blockers 223 (30.9) 213 (29.6) 0.59
Digitalis 33 (4.6) 30 (4.2) 0.71
Diuretics 268 (37.1) 264 (36.7) 0.86
Aldosterone blockers 43 (6.0) 49 (6.8) 0.51
Statins 196 (27.1) 172 (23.9) 0.16
Oral anticoagulants 398 (55.1) 417 (57.9) 0.29
Aspirin 206 (28.5) 189 (26.2) 0.33
* Plus–minus values are means ±SD. P values were calculated with the use of chi-square tests, with the exception of  
P values for comparisons of age, body-mass index, blood pressure, and heart rate, which were calculated with the use 
of t-tests. ACE denotes angiotensin-converting enzyme, and LVEF left ventricular ejection fraction.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Atrial fibrillation alone was defined as atrial fibrillation without coexisting cardiovascular conditions but with left atrial 
dilatation.
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to a yearly hazard rate of 69%) and a withdrawal 
rate of 15%. On the basis of these calculations, 
we planned to enroll 1402 patients. 
All analyses were performed in the intention-
to-treat population. Comparisons of the first pri-
mary end point (time to the first recurrence of 
atrial fibrillation) between the treatment and pla-
cebo groups were performed with the use of a 
log-rank test. We estimated the size of the effect 
by calculating hazard ratios with the use of a 
Cox proportional-hazards model. In a further 
analysis, we included as covariates all the base-
line clinical characteristics that were assessed in 
the study patients. For the second primary end 
point (the proportion of patients with more than 
one recurrence of atrial fibrillation), we assessed 
the treatment effect by using a logistic-regression 
model to calculate odds ratios, with and without 
adjustment for all baseline covariates.
We adjusted the overall significance level of 
0.05 to account for the inclusion of two primary 
end points. The first (time to the first recurrence 
of atrial fibrillation) was tested at a two-sided sig-
nificance level of 0.04, and the second (proportion 
of patients with more than one episode of atrial 
fibrillation), at a two-sided significance level of 
0.01. Thus, confidence intervals of 96% and 99% 
were calculated for the first and the second pri-
mary end points, respectively.
We also calculated hazard ratios with 95% con-
fidence intervals, using the Cox regression mod-
el to assess the effect of valsartan on the second-
ary end points and in the prespecified subgroups. 
For the between-group comparisons of those sec-
ondary end points that were expressed as propor-
tions or mean values, we used a chi-square test or 
t-test. We performed Cox analyses of the primary 
outcome to test for an unfavorable outcome in 
prespecified subgroups by fitting a Cox model 
with one term representing the treatment group, 
one term representing the covariate of interest, 
and an interaction term to test for heterogeneity 
of the effect of valsartan. Changes in systolic blood 
pressure were analyzed by means of analysis of 
variance, with adjustment for baseline values, and 
were reported as least-square means ±SE.
The reported P values are two-sided and not 
adjusted for multiple testing. All analyses were 
conducted with SAS software, version 9.2 (SAS 
Institute).
R ESULT S
Patients
From November 2004 through January 2007, we 
enrolled 1442 patients at 114 centers; 722 patients 
were randomly assigned to the valsartan group, 
and 720 to the placebo group. There were no clin-
ically relevant differences between the two groups 
in baseline characteristics (Table 1), except for a 
higher prevalence of coronary artery disease and 
peripheral arterial disease in the valsartan group 
than in the placebo group. A total of 85.4% of the 
patients had a history of hypertension, 14.6% had 
diabetes, and 7.9% had heart failure, left ventric-
ular dysfunction, or both. At the time of random-
ization, 34.7% of the patients were receiving ami-
odarone, 57.0% were receiving ACE inhibitors, 
30.2% were receiving beta-blockers, and 56.5% 
were receiving anticoagulant drugs (Table 1).
The target dose of 320 mg of the study drug 
was achieved at 4 weeks in 83.1% of the patients 
assigned to valsartan and in 85.2% of those as-
signed to placebo, and this dose was maintained 
in similar proportions of patients until the end of 
the study. Only five patients in the valsartan group 
and five in the placebo group had to have the study 
drug withdrawn because they could not tolerate 
a daily dose of 160 mg.
By 8 weeks, the least-square mean systolic 
blood pressure was reduced by 3.91±0.60 mm Hg 
in the valsartan group and by 1.07±0.60 mm Hg 
in the placebo group (P<0.001). By the end of the 
study, the reductions were 4.13±0.63 mm Hg in 
the valsartan group and 1.96±0.62 mm Hg in the 
placebo group (P = 0.01). The mean heart rate was 
unchanged from baseline values at 8 weeks and 
at the end of the study (data not shown). The over-
all median duration of follow-up was 365 days 
(interquartile range, 359 to 372). We had follow-up 
data on survival for all the patients and follow-
up data on the first recurrence of atrial fibrilla-
tion for almost all the patients (95.5%). More than 
80% of expected transtelephonic recordings were 
actually transmitted.
Primary End Points
At 1 year, 51.4% of the patients (371 of 722) in the 
valsartan group and 52.1% (375 of 720) in the pla-
cebo group had had a recurrence of atrial fibril-
lation (hazard ratio, 0.98; 96% confidence interval 
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[CI], 0.85 to 1.14; P = 0.83) (Fig. 1A). After adjust-
ment for all baseline variables reported in Table 1, 
the adjusted hazard ratio was 0.97 (96% CI, 0.83 
to 1.14; P = 0.73). Overall, the median times from 
randomization to the first recurrence of atrial fi-
brillation were 295 days in the valsartan group 
and 271 days in the placebo group.
More than one episode of atrial fibrillation oc-
curred in 26.9% of the patients (194 of 722) in the 
valsartan group, as compared with 27.9% of the 
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Figure 1. Kaplan–Meier Curves for the Time to the First Recurrence of Atrial Fibrillation.
Panel A includes data from the whole cohort, and Panel B data from the 1255 patients who were in sinus rhythm  
at 15 days.
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patients (201 of 720) in the placebo group (odds 
ratio, 0.95; 99% CI, 0.70 to 1.29; P = 0.66). After 
adjustment for all baseline variables reported in 
Table 1, the adjusted odds ratio was 0.89 (99% 
CI, 0.64 to 1.23; P = 0.34). 
Secondary Analyses and End Points
Among the 1255 patients who were in sinus rhythm 
15 days after study entry, there was no significant 
difference between the valsartan and placebo 
groups with respect to the rates of recurrence of 
atrial fibrillation (47.7% and 48.4%, respectively; 
hazard ratio, 0.96; 96% CI, 0.81 to 1.13; P = 0.59) 
(Fig. 1B). Similar results were obtained from a 
post hoc analysis of data from the 1254 patients 
who were in sinus rhythm at week 8, by which 
time the patients would have been receiving the 
target dose of valsartan (rate of recurrence, 42.7% 
Table 2. Secondary End Points.*
End Point
Valsartan
(N = 722)
Placebo
(N = 720)
Hazard Ratio
(95% CI)
P 
Value†
Clinical events — no. of patients (%)
Hospitalization for any reason 149 (20.6) 143 (19.9) 1.05
(0.83–1.32)
0.70
Hospitalization for cardiovascular event 114 (15.8) 122 (16.9) 0.93
(0.72–1.20)
0.59
Death or nonfatal thromboembolic event 18 (2.5) 9 (1.2) 2.03
(0.91–4.52)
0.08
Death 8 (1.1) 7 (1.0) 1.16
(0.42–3.19)
0.78
Thromboembolic events — no. of patients (%) 10 (1.4) 2 (0.3) 5.06 
(1.11–23.11)
0.04
Ischemic stroke 4 (0.6) 0
Transient ischemic attack 3 (0.4) 1 (0.1)
Other 3 (0.4) 1 (0.1)
Episodes of atrial fibrillation — no. of patients (%) 0.88
0 351 (48.6) 345 (47.9)
1 177 (24.5) 174 (24.2)
2 67 (9.3) 70 (9.7)
3–5 87 (12.0) 82 (11.4)
>5 40 (5.5) 49 (6.8)
Arrhythmia-related events 
Sinus rhythm at 8-wk visit — no. of patients/total no. (%) 627/684 (91.7) 627/693 (90.5) 0.44
Sinus rhythm at study-end visit — no. of patients/ 
total no. (%)
565/667 (84.7) 559/676 (82.7) 0.32
Ventricular rate at first episode of atrial fibrillation‡ 109.6±28.4 107.5±29.6 0.33
Duration of first episode of atrial fibrillation —  
no. of patients/total no. (%)
0–7 days 177/371 (47.7) 172/375 (45.9) 0.26
>7 days 89/371 (24.0) 109/375 (29.1)
Data not available 105/371 (28.3) 94/375 (25.1)
* Plus–minus values are means ±SD.
† P values for clinical and thromboembolic events were calculated with the use of Cox proportional-hazards models;  
P values for episodes of atrial fibrillation, sinus rhythm at 8 weeks and at study end, and duration of first episode of 
atrial fibrillation were calculated with chi-square tests; and the P value for ventricular rate at the first episode of atrial  
fibrillation was calculated with a t-test.
‡ The total number of patients who had at least one episode of atrial fibrillation was 746 (371 in the valsartan group, and 
375 in the placebo group).
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in the valsartan group and 44.0% in the placebo 
group; hazard ratio, 0.96; 96% CI, 0.80 to 1.14; 
P = 0.62). We did not observe significant differ-
ences in any of the secondary end points (Table 2), 
with the exception of thromboembolic events, 
which occurred in 10 patients in the valsartan 
group as compared with 2 in the placebo group 
(hazard ratio, 5.06; 95% CI, 1.11 to 23.11; P = 0.04).
When all episodes of atrial fibrillation in a pa-
tient were counted, no significant differences were 
evident between the valsartan group and the pla-
cebo group with respect to any number of recur-
rences of atrial fibrillation per patient (Table 2). 
About half of the total number of first recurrences 
of atrial fibrillation were symptomatic, with no 
significant difference between the two groups in 
the rate of symptomatic atrial fibrillation (24.0% 
in the valsartan group and 23.1% in the placebo 
group, P = 0.77).
Subgroup Analyses
Hazard ratios for the first recurrence of atrial fi-
brillation were similar in all predefined subgroups 
of patients (Fig. 2). A nonsignificant trend toward 
a lower incidence of recurrence of atrial fibrilla-
tion was apparent in the valsartan group among 
the 114 patients who presented with heart failure 
or left ventricular dysfunction (hazard ratio, 0.81; 
95% CI, 0.48 to 1.35; P = 0.41).
Safety
The study drug was permanently discontinued in 
107 (14.8%) of the patients in the valsartan group 
and 76 (10.6%) of those in the placebo group 
(P = 0.02). Of these discontinuations, 26 in the val-
sartan group and 12 in the placebo group were 
attributed to adverse drug reactions (Table 3). Se-
rious adverse reactions occurred in two patients 
in the valsartan group (severe hypotension in one 
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Figure 2. Effect of Treatment with Valsartan on the Risk of a First Recurrence of Atrial Fibrillation (AF) in Prespeci-
fied Subgroups.
Hazard ratios are indicated by solid squares, which are proportional in size to the number of people in each group, 
and horizontal lines represent the 95% confidence intervals, as calculated by a Cox proportional-hazards model, ex-
cept in the case of the overall population, for which 96% confidence intervals are shown. AF alone refers to atrial fi-
brillation without coexisting cardiovascular conditions but with left atrial dilatation. ACE denotes angiotensin-con-
verting enzyme, HF heart failure, and LVD left ventricular dysfunction.
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patient and renal dysfunction plus hyperkalemia 
in the other). The proportion of patients who had 
at least one doubling of the serum creatinine 
level or who had a serum creatinine level that was 
higher than 3.5 mg per deciliter (309.4 μmol per 
liter) during the follow-up period was 0.7% in the 
valsartan group and 0.9% in the placebo group 
(P = 0.77). The proportion of patients in whom at 
least one measurement of the serum potassium 
level was higher than 5.5 mmol per liter during 
the follow-up period was 5.6% in the valsartan 
group and 2.4% in the placebo group (P = 0.002).
DISCUSSION
In the GISSI-AF trial, we tested the effect of an 
ARB, valsartan, on the recurrence of atrial fibril-
lation in patients who had a history of atrial fi-
brillation associated with cardiovascular disease, 
diabetes, or left atrial enlargement. In these pa-
tients, the addition of valsartan to established ther-
apies for atrial fibrillation and for coexisting car-
diovascular conditions did not reduce the risk of 
either a first recurrence or multiple recurrences 
of atrial fibrillation. These results were consistent 
across all predefined subgroups. Our findings do 
not support the original hypothesis of a benefi-
cial role of blockers of the renin–angiotensin–
aldosterone system in the prevention of recur-
rent atrial fibrillation.
Only four previously published studies, in which 
a total of 665 patients were enrolled, specifically 
evaluated the role of ARBs in the secondary pre-
vention of atrial fibrillation.25-28 The results of 
three of these studies suggested a beneficial ef-
fect; in all three of these trials, amiodarone was 
given to all patients as part of the trial proto-
col.25-27 In contrast, in the subgroup of patients 
treated with amiodarone in our trial, valsartan did 
not have a significant beneficial effect.
Our trial did not address the efficacy of agents 
that block the renin–angiotensin–aldosterone sys-
tem for the primary prevention of atrial fibrilla-
tion. Previous trials and meta-analyses have sug-
gested a more pronounced effect of these agents 
when they are used for primary prevention,19-24,29,30 
perhaps because of a beneficial influence on the 
pathophysiological substrate of atrial fibrillation 
(i.e., structural or electrical remodeling, or both) 
before the occurrence of irreversible atrial remod-
eling. We also did not evaluate the efficacy of ACE-
inhibitor therapy, which has been reported to be 
similar to the efficacy of ARB therapy.29,30
One limitation of many large clinical trials in 
which the occurrence of atrial fibrillation is not 
a primary end point is the method used to detect 
recurrences of atrial fibrillation. Such trials often 
rely on the results of electrocardiography per-
formed at scheduled office visits or on the pa-
tient’s report of symptoms (as in the Losartan 
Intervention for Endpoint Reduction in Hyperten-
sion [LIFE], Candesartan in Heart Failure: Assess-
ment of Reduction in Mortality and Morbidity 
[CHARM], and Valsartan Antihypertensive Long-
term Use Evaluation [VALUE] trials).21,23,24 As a 
result, these trials tend to show lower rates of de-
tection of atrial fibrillation than trials, like ours, 
that use frequent transtelephonic monitoring.
One limitation of our trial is the relatively short 
duration (1 year) of clinical follow-up. Some of the 
large trials mentioned above (LIFE, CHARM, and 
VALUE) had mean follow-up intervals that were 
longer than 3 years. The time required for the pu-
tative effects of ARBs on atrial remodeling is not 
well defined. However, we did not detect even a 
modest trend in favor of valsartan therapy during 
the course of our trial, suggesting that such an 
effect would not be anticipated with a longer fol-
low-up period.
Conversely, it seems unlikely that the expected 
benefit of ARB therapy would occur within the 
Table 3. Adverse Reactions Leading to Permanent Discontinuation of the Study 
Drug.*
Adverse Reaction
Valsartan
(N = 722)
Placebo
(N = 720)
no. of patients
Total 26 12
Vertigo 3 1
Asthenia 1 1
Symptomatic hypotension 7 3
Cutaneous allergy 2 2
Hyperkalemia 2 0
Renal dysfunction 3 1
Gastrointestinal disorder 2 1
Hair loss 1 2
Muscle symptoms 0 1
Other† 5 0
* Two serious adverse drug reactions in patients in the valsartan group — hypo-
tension in one patient and renal dysfunction plus hyperkalemia in the other 
— resolved without sequelae.
† Included in this category are epistaxis in 1 patient, an increase in liver enzyme 
levels in 1, an allergic reaction in 1, and cough in 2.
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first few days of starting treatment. Early recur-
rences of atrial fibrillation after cardioversion are 
probably due to short-term electrical remodeling 
of atria,32 which tends to normalize within days 
or weeks if sinus rhythm is again restored. For this 
reason, we planned a secondary analysis that was 
limited to data on patients who were in sinus 
rhythm at the first follow-up visit, on day 15. This 
analysis did not show any effect of valsartan on 
the recurrence of atrial fibrillation. Similar results 
were obtained from a post hoc analysis of data 
from patients who were in sinus rhythm at week 8, 
to account for the time needed to reach the target 
dose of valsartan.
The significant excess of thromboembolic 
events in the valsartan group was unexpected, and 
we believe that this result may be a chance find-
ing. Of note, the rate of thromboembolic events 
in the placebo group in our trial was much lower 
than expected and was lower than previously re-
ported rates in similar patient populations.33,34
In conclusion, we evaluated the potential ben-
efit of adding 320 mg of valsartan daily to stan-
dard therapy in patients who had a history of 
atrial fibrillation associated with cardiovascular 
disease, diabetes, or left atrial enlargement. At 
1 year, we found no significant reduction in the 
incidence of recurrent atrial fibrillation among 
patients receiving valsartan as compared with 
those receiving placebo.
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